| [Objective]Based on the Telomerase activity and Survivin expression in tumor tissue, thearticle explored whether the inhibition of lung cancer-I prescription on mice isrelated with Lewis lung telomerase activity and Survivin expression, which canoffer the scientific clinical experimental basis for its application and promotion andeven for making personal treating program for integration of western medicine andChinese medicine.[Methods]To copy mice with Lewis lung model, the modeling, the mouse with Lewis lungare divided into Tumor-bearing control group, CTX group, Lung cancer-Iprescription group, Consolidated group (CTX+lung cancer-I prescription).Administered12days later, laboratory mouse are killed to take specimens bybreaking necks. Compare mouse tumor weight, inhibition rate; biopsy of tumortissue, and observe the histo-pathological changes; TRAP real-time quantitative PCRdetection of telomerase activity; immunohistochemical SABC assay of inhibitor ofapoptosis protein Survivin expression, and finally use SPSS17.0statistics softwareto carry out statistical analysis to the data.[Results]1. After six days Lewis lung carcinoma inoculation, mouse right forelimb armpitskin can be touched grain size of the tumor mass, it marks that modeling got success.2. Tumor weight comparison and tumor inhibition rate measurement: 2.1The weight of tumor: the Tumor-bearing control group (6.81±1.36g) comparedto Lung cancer-I prescription group (5.30±0.90g) the average tumor weight lowerthan the tumor-bearing control group, the difference was statistically significant (P<0.05), the CTX group(2.83±1.69g) and Consolidated group (2.36±1.05g) theaverage tumor weight was significantly lower than the Tumor-bearing control group,the difference was statistically significant (P <0.01); compared with Lung cancer-Iprescription group, the CTX group and group average the tumor weight wassignificantly lower than Lung cancer-I prescription group, the difference wasstatistically significant (P <0.01); compared with the CTX group, Consolidatedgroup average tumor weight less than the CTX group, the difference was statisticallysignificant (P <0.05).2.2The tumor inhibition rate measurement: Consolidated group of tumor inhibitionhas strongest effect, the inhibition rate was65.31%, the CTX group, followed bythe inhibition rate was58.36%t, the weakest Lung cancer-I prescription group, theinhibition rate of22.15%3. Histopathology: the light microscope, each treatment group and Tumor-bearingcontrol group, tumor cell density decreased necrosis area increased atypia cells andpathological mitotic reduce increased interstitial infiltration of inflammatory cells.4. Telomerase activity in TRAP quantitative real-time detection: telomeraseactivity using the Ct value, the Ct value, the template size is small, indicating thattelomerase activity is low, the Ct value, number of template, indicating that hightelomerase activity. Compare Lung cancer-I prescription group (21.48±1.62) andTumor-bearing control Ct value of telomerase activity close to the Control group(20.17±1.43) and Tumor-bearing, no statistically significant difference, the CTXgroup (29.42±1.48) and the Consolidated group (30.86±1.75), telomerase activityCt value was significantly higher than the Tumor-bearing control group, thedifference was statistically significant (P <0.01); compared with Lung cancer Iprescription group, the CTX group telomerase activity Ct value was significantlyhigher in Lung cancer-I prescription group, the difference was statistically significant (P <0.01); compared with the CTX group, Consolidated group telomeraseactivity Ct value higher than the CTX group, the difference was statisticallysignificant (P <0.05).5. The expression of Survivin Detection: Tumor-bearing control group (0.41±0.10%) compared to Lung cancer-I prescription group (0.34±0.07%) of Survivin LIaverage lower than the Tumor-bearing control group, the difference was statisticallysignificant (P <0.05), the CTX group (0.25±0.08%) and Consolidated group (0.17±0.05%) average of Survivin LI was significantly lower than the Tumor-bearingcontrol group, the difference was statistically significant (P <0.01); compared withthe Lung cancer-I prescription group, the CTX group and Consolidated group ofSurvivin LI average significantly lower than Lung cancer-I prescription group, andthe difference was statistically significant (P <0.01); compared with the CTX group,the average of the Consolidated group of Survivin LI lower than the CTX group, thedifference was statistically significant (P <0.05).[Conclusions]1. Lung cancer-I prescription has inhibitory effects on mice with Lewis lung cancer,in combination with chemotherapy drugs CTX has synergies.2. Lung cancer-I prescription is not obvious for decreasing mice with Lewis lungcancer and telomerase activity, but in combination with chemotherapy drugs CTX, itcan enhance the downward effect of CTX on Lewis lung telomerase activity.3. Lung cancer-I prescription can inhibit the apoptosis protein Survivin expressionfor mice with Lewis lung cancer, and it can enhance the inhibitory effect of CTX onthe expression of Survivin in combination with chemotherapy drugs CTX. |
PDF Full Text Request